This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Hoppe RT , Advani RH , Ai WZ , Ambinder RF , Aoun P , Bello CM , Benitez CM , Bernat K , Bierman PJ , Blum KA , Chen R , Dabaja B , Forero A , Gordon LI , Hernandez-Ilizaliturri FJ , Hochberg EP , Huang J , Johnston PB , Kaminski MS , Kenkre VP , Khan N , Maloney DG , Mauch PM , Metzger M , Moore JO , Morgan D , Moskowitz CH , Mulroney C , Poppe M , Rabinovitch R , Seropian S , Smith M , Winter JN , Yahalom J , Burns J , Ogba N , Sundar H
Hodgkin lymphoma version 1.2017
JNCCN Journal of the National Comprehensive Cancer Network. 2017 May;15(5) :608-638
PMID: 28476741 URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019066211&partnerID=40&md5=88f4fa5004aa044732699642af5850d2
AbstractThis portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects.
NotesExport Date: 2 June 2017